ProQR Therapeutics’ Director Buys 14,595 Options – A Quiet Bet on a Genetic Therapy Breakthrough
ProQR insiders buy options, signaling confidence in a rising biotech stock and promising genetic‑therapy pipeline.
3 minutes to read
PROQR THERAPEUTICS NV
Director Gylvin Lykke Buys 14,495 ProQR Options, Signaling Long‑Term Confidence in the Biotech Pipeline
ProQR insider Lykke buys 14,495 options, signaling confidence in the company’s gene‑therapy pipeline and potential upside amid market volatility.
2 minutes to read